Literature DB >> 9892406

Respiratory syncytial virus infection prolongs methacholine-induced airway hyperresponsiveness in ovalbumin-sensitized mice.

R S Peebles1, J R Sheller, J E Johnson, D B Mitchell, B S Graham.   

Abstract

Severe respiratory syncytial virus (RSV)-induced disease is associated with childhood asthma and atopy. We combined models of allergen sensitization and RSV infection to begin exploring the immunologic interactions between allergic and virus-induced airway inflammation and its impact on airway hypersensitivity. Airway resistance was measured after methacholine challenge in tracheally intubated mice by whole body plethysmography. Lung inflammation was assessed by bronchoalveolar lavage (BAL) and histopathology. RSV infection alone did not cause significant airway hyperresponsiveness (AHR) to methacholine. Ovalbumin (OVA)-induced AHR lasted only a few days past the discontinuance of OVA aerosol in mice that were ovalbumin sensitized and mock infected. In contrast, OVA-sensitized mice infected with RSV during the OVA aerosol treatments (OVA/RSV) had AHR for more than 2 weeks after infection. However, 2 weeks after either RSV or mock infection, OVA/RSV mice had significantly more lymphocytes found during BAL than OVA mice, whereas the OVA and OVA/RSV groups had the same number of eosinophils. Histopathologic analysis confirmed an increased inflammation in the lungs of OVA/RSV mice compared with OVA mice. In addition, OVA/RSV mice had a more widespread distribution of mucus in their airways with increased amounts of intraluminal mucus pools compared with the other groups. Thus, prolonged AHR in RSV-infected mice during ovalbumin-sensitization correlates with increased numbers of lymphocytes in BAL fluid, increased lung inflammation, and mucus deposition in the airways, but not with airway eosinophilia. A further understanding of the immunologic consequences of combined allergic and virus-induced airway inflammation will impact the management of diseases associated with airway hyperreactivity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9892406     DOI: 10.1002/(sici)1096-9071(199902)57:2<186::aid-jmv17>3.0.co;2-q

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  40 in total

Review 1.  Toward primary prevention of asthma. Reviewing the evidence for early-life respiratory viral infections as modifiable risk factors to prevent childhood asthma.

Authors:  Amy S Feldman; Yuan He; Martin L Moore; Marc B Hershenson; Tina V Hartert
Journal:  Am J Respir Crit Care Med       Date:  2015-01-01       Impact factor: 21.405

Review 2.  The role of regulatory T cells in allergy.

Authors:  Maria A Curotto de Lafaille; Juan J Lafaille
Journal:  Springer Semin Immunopathol       Date:  2003-10-22

Review 3.  Pathogenesis of respiratory syncytial virus infection in the murine model.

Authors:  R Stokes Peebles; Barney S Graham
Journal:  Proc Am Thorac Soc       Date:  2005

4.  Heat Shock-Related Protein 20 Peptide Decreases Human Airway Constriction Downstream of β2-Adrenergic Receptor.

Authors:  Alex Banathy; Joyce Cheung-Flynn; Kasia Goleniewska; Kelly L Boyd; Dawn C Newcomb; R Stokes Peebles; Padmini Komalavilas
Journal:  Am J Respir Cell Mol Biol       Date:  2016-08       Impact factor: 6.914

5.  Respiratory syncytial virus infection and G and/or SH protein expression contribute to substance P, which mediates inflammation and enhanced pulmonary disease in BALB/c mice.

Authors:  R A Tripp; D Moore; J Winter; L J Anderson
Journal:  J Virol       Date:  2000-02       Impact factor: 5.103

6.  Differential immune responses and pulmonary pathophysiology are induced by two different strains of respiratory syncytial virus.

Authors:  Nicholas W Lukacs; Martin L Moore; Brian D Rudd; Aaron A Berlin; Robert D Collins; Sandra J Olson; Samuel B Ho; R Stokes Peebles
Journal:  Am J Pathol       Date:  2006-09       Impact factor: 4.307

7.  IL-17A inhibits airway reactivity induced by respiratory syncytial virus infection during allergic airway inflammation.

Authors:  Dawn Catherine Newcomb; Madison G Boswell; Sara Reiss; Weisong Zhou; Kasia Goleniewska; Shinji Toki; Melissa T Harintho; Nicholas W Lukacs; Jay K Kolls; R Stokes Peebles
Journal:  Thorax       Date:  2013-02-19       Impact factor: 9.139

8.  Anti-respiratory syncytial virus (RSV) neutralizing antibody decreases lung inflammation, airway obstruction, and airway hyperresponsiveness in a murine RSV model.

Authors:  Asunción Mejías; Susana Chávez-Bueno; Ana María Ríos; Jesús Saavedra-Lozano; Mónica Fonseca Aten; Jeanine Hatfield; Payal Kapur; Ana María Gómez; Hasan S Jafri; Octavio Ramilo
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

9.  Respiratory syncytial virus and reactive airway disease.

Authors:  Matthew T Lotz; Martin L Moore; R Stokes Peebles
Journal:  Curr Top Microbiol Immunol       Date:  2013       Impact factor: 4.291

10.  Respiratory syncytial virus (RSV) G glycoprotein is not necessary for vaccine-enhanced disease induced by immunization with formalin-inactivated RSV.

Authors:  Teresa R Johnson; Michael N Teng; Peter L Collins; Barney S Graham
Journal:  J Virol       Date:  2004-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.